top of page
Poznan, Poland

Zuzanna Stern

Zuzanna, a dynamic professional boasting over 20 years of expertise, emerges as a Chief Executive, R&D Team Leader, Inventor, and serial Entrepreneur. She is passionate about using the latest technology to make the world a better place, and she consistently works towards making a positive impact.


As the innovative mind behind multiple companies spanning education, industrial robotics and automation, sustainable design, and biotechnology, Zuzanna showcases a versatile skill set. This diverse background not only equips her with a unique perspective but also empowers her to lead multidisciplinary international teams, fostering innovation in the lives of others.


Currently serving as the Founder and President of Cellivia, a biotech company, where she combines expertise in medicine, biology, and robotics. Here, the focus lies on developing technologies for manufacturing medicinal products based on stem cells and exosomes. Cellivia also proudly holds the title of the world's first gingiva biobank, actively banking biological materials for advanced therapies.


Beyond her significant contributions at Cellivia, Zuzanna’s dedication to philanthropy reaches deeply into the educational sector and beyond. Anchored by her firm belief in the power of knowledge to enact change, she supports initiatives designed to make a tangible difference in people’s lives. Her conviction in the transformative power of collaboration is demonstrated through her active role in the Global Healthcare Leaders Foundation. As a Founder and co- Executive Director, Zuzanna not only advocates for the mission but also embodies the spirit of collective effort and impact, striving to advance global healthcare through unity and shared vision.


Zuzanna's main goal is to use her expertise to contribute to creating a better world for future generations. As a dedicated leader, innovator, and philanthropist, she continues her mission to improve the healthcare system with a strong commitment to excellence and positive change, always with a focus on the best interests of patients.

"Biotech Horizons: The Shift from Conventional Pharmaceuticals to Biotechnical Therapies""

bottom of page